Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Sai Ping LauNadine van MontfoortPriscilla KindermanMelanie LukkesLarissa KlaaseMenno van NimwegenMandy van GulijkJasper DumasDana A M MustafaSanne L A LievenseChristianne GroeneveldtRalph StadhoudersYunlei LiAndrew Peter StubbsKoen A MarijtHeleen VromanSjoerd H van der BurgJoachim AertsThorbald van HallFloris DammeijerCasper H J van EijckPublished in: Journal for immunotherapy of cancer (2021)
These results demonstrate the potency of DC therapy in combination with CD40-stimulation for the treatment of pancreatic cancer and provide directions for near future clinical trials.